Back to Search
Start Over
Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
- Source :
-
Cancer [Cancer] 2008 May 15; Vol. 112 (10), pp. 2202-10. - Publication Year :
- 2008
-
Abstract
- Background: The purpose was to identify the factors predictive of recurrence and survival in patients with high-risk (stage I, grade 3; stage IC, stage II, or clear cell) epithelial ovarian cancer after adjuvant therapy.<br />Methods: Data was extracted from patients who underwent primary surgery followed by adjuvant therapy in 2 randomized trials by the Gynecologic Oncology Group (Protocols 95 and 157). Kaplan-Meier survival estimates and Cox proportional hazards model adjusted for covariates were used for analyses.<br />Results: Of 506 patients (median age = 56.2 years), 347 (68.6%) had stage I and 159 (31.4%) had stage II cancers. The 5-year recurrence-free (RFS) and overall survivals (OS) were 75.5% and 81.7%, respectively. On multivariate analysis, older age, higher stage, higher grade, and malignant cytology were independent prognostic factors predictive for recurrence and poorer survival. The risk of recurrence was higher for those >/=60 versus < 60 years (hazards ratio [HR] = 1.57, 95% confidence interval [CI], 1.12-2.19), stage II (stage II: HR = 2.70, 95% CI, 1.41-5.16) versus stage IA or IB, grade 2 (HR = 1.84, 95% CI, 1.04-3.27) and grade 3 (HR = 2.47, 95% CI, 1.39-4.37) versus grade 1, and positive versus negative cytology (HR = 1.72, 95% CI, 1.21-2.45). By using these factors in a prognostic index, those with low-risk (no or 1 risk factor), intermediate-risk (2 factors), and high-risk (3-4 risk factors) disease had survivals of 88%, 82%, and 75%, respectively (P < .05).<br />Conclusions: Age, stage, grade, and cytology are important prognostic factors in high-risk early-stage epithelial ovarian cancer. This information may be used in the design of future clinical trials.<br /> ((c) 2008 American Cancer Society.)
- Subjects :
- Adenocarcinoma, Clear Cell drug therapy
Adenocarcinoma, Clear Cell mortality
Adenocarcinoma, Clear Cell pathology
Adenocarcinoma, Mucinous drug therapy
Adenocarcinoma, Mucinous mortality
Adenocarcinoma, Mucinous pathology
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Carcinoma, Endometrioid drug therapy
Carcinoma, Endometrioid mortality
Carcinoma, Endometrioid pathology
Cystadenocarcinoma, Serous drug therapy
Cystadenocarcinoma, Serous mortality
Cystadenocarcinoma, Serous pathology
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Recurrence, Local drug therapy
Neoplasm Recurrence, Local mortality
Neoplasm Recurrence, Local pathology
Neoplasm Staging
Neoplasms, Glandular and Epithelial drug therapy
Neoplasms, Glandular and Epithelial mortality
Ovarian Neoplasms drug therapy
Ovarian Neoplasms mortality
Prognosis
Risk Factors
Survival Rate
Neoplasms, Glandular and Epithelial pathology
Ovarian Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 0008-543X
- Volume :
- 112
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 18348296
- Full Text :
- https://doi.org/10.1002/cncr.23390